MM-RCT: Moving Mindfully for Freezing of Gait

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT05923229
Collaborator
(none)
30
1
2
12.3
2.4

Study Details

Study Description

Brief Summary

The investigators will conduct an randomized controlled trial (RCT) among people with Parkinson disease (PD) and freezing of gait (FOG) to evaluate the feasibility of a mindfulness intervention compared to a educational program about FOG. FOG is a severe motor disturbance that prevents people from stepping normally and is associated with anxiety, frustration, sedentary behaviors, poorer quality of life, and falls. Mindfulness-Based Stress Reduction (MBSR) is an evidence-based practice that creates a culture to reduce stress and anxiety by increasing conscious awareness and self-compassion. In this study, the investigators will develop a mindfulness-based walking intervention to address both mental health and mobility challenges that constitute FOG.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness Based Walking Therapy (MBWT)
  • Other: Freezing of Gait (FOG) Education
N/A

Detailed Description

Conduct pilot randomized clinical trial to evaluate feasibility and acceptability of the standardized Mindfulness Based Walking Therapy (MBWT) program. Using the standardized MBWT protocol devised during earlier aims of this study, the investigators will randomize 24 people with PD+FOG to MBWT or usual care (i.e., medical management and FOG education), examining feasibility elements. The investigators will also conduct follow-up evaluations to monitor burden and continued usage of mindfulness.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Moving Mindfully: A MBSR-Centered Approach to Freezing in Parkinson Disease - Randomized Control Trial
Actual Study Start Date :
Jun 7, 2023
Anticipated Primary Completion Date :
Apr 15, 2024
Anticipated Study Completion Date :
Jun 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness-Based Walking Therapy (MBWT)

Participants will receive the MBWT intervention.

Behavioral: Mindfulness Based Walking Therapy (MBWT)
MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.

Placebo Comparator: Freezing of Gait (FOG) Education

Participants will receive educational materials about FOG and track their usual care.

Other: Freezing of Gait (FOG) Education
Participants will receive materials to read weekly about FOG and track their usual care regimens.

Outcome Measures

Primary Outcome Measures

  1. Recruitment of Sample: Number of Participants Recruited [14 weeks]

    The investigators will count the number of participants recruited to determine if the feasibility objective of recruitment is met. The investigators benchmark for recruitment is defined as recruiting a target sample of 24 participants to randomize.

  2. Attendance of Participants: Number of Participants at Each Session [14 weeks]

    The investigators will count the number of participants at each session to determine if the feasibility objective of attendance is met. The investigators benchmark for attendance is defined as at least 80% of participants attending each session.

  3. Retention of Participants: Number of Sessions Each Participant Completes [14 weeks]

    The investigators will count the number of sessions each participant attends to determine if the feasibility objective of retention is met. The investigators benchmark for retention is defined as participants 80% of the sessions.

  4. Adherence: Number of Hours Participants Practice Mindfulness at Home [14 weeks]

    The investigators will ask participants to track the number of hours spent practicing mindfulness at home to determine if the feasibility objective of adherence is met. The investigators benchmark for adherence is defined as participants completing 70% of daily home assignment hours.

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosed by a neurologist with idiopathic Parkinson disease;

  • age 55 and older;

  • a score on the Hoehn & Yahr (H&Y) scale between I-IV;

  • history of freezing of gait;

  • able to provide informed consent;

  • experience fear or worry in relation to their freezing of gait;

  • able to walk independently with or without an assistive device for at least five minutes; and

  • stable medication regimen for one month prior to enrollment.

Exclusion Criteria:
  • have evidence of dementia (Montreal Cognitive Assessment (MOCA) < 18) to ensure understanding of materials;

  • are under consideration for deep brain stimulation surgery within the next six months; neurologic condition other than PD;

  • inability to cooperate with the protocol;

  • language, visual, or hearing barriers to participation; or

  • history of orthopedic or other medical problems that limit ability to participate safely in the intervention.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University School of Medicine Saint Louis Missouri United States 63108

Sponsors and Collaborators

  • Washington University School of Medicine

Investigators

  • Principal Investigator: Gammon Earhart, PhD, Washington University School of Medicine
  • Principal Investigator: Kerri Rawson, PhD, Washington University School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gammon M Earhart, Professor, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT05923229
Other Study ID Numbers:
  • 202304132
First Posted:
Jun 28, 2023
Last Update Posted:
Jun 29, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 29, 2023